Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IPHA
stocks logo

IPHA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2020Q4
27.11M
+103.36%
0.000
-100%
Estimates Revision
The market is revising Downward the revenue expectations for Innate Pharma S.A. (IPHA) for FY2025, with the revenue forecasts being adjusted by -80.26% over the past three months. During the same period, the stock price has changed by -6.82%.
Revenue Estimates for FY2025
Revise Downward
down Image
-80.26%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-186.43%
In Past 3 Month
Stock Price
Go Down
down Image
-6.82%
In Past 3 Month
Wall Street analysts forecast IPHA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IPHA is 5.75 USD with a low forecast of 2.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast IPHA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IPHA is 5.75 USD with a low forecast of 2.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
2 Hold
0 Sell
Moderate Buy
Current: 1.910
sliders
Low
2.00
Averages
5.75
High
8.00
Current: 1.910
sliders
Low
2.00
Averages
5.75
High
8.00
H.C. Wainwright
H.C. Wainwright
Neutral -> Buy
upgrade
$5
2025-10-29
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$5
2025-10-29
upgrade
Neutral -> Buy
Reason
H.C. Wainwright upgraded Innate Pharma to Buy from Neutral with a $5 price target. The company announced its intention to file an application with the FDA for an accelerated approval of lacutamab and initiate a Phase 3 study to evaluate the drug as a therapy for cutaneous T-cell lymphoma, the analyst tells investors in a research note. The firm recommends buying the stock's recent weakness.
Lucid Capital
NULL
to
Buy
initiated
$8
2025-10-23
Reason
Lucid Capital
Price Target
$8
2025-10-23
initiated
NULL
to
Buy
Reason
Lucid Capital initiated coverage of Innate Pharma with a Buy rating and $8 price target. Innate is a clinical-stage biotechnology company focused on developing antibodies and antibody-drug conjugates for oncology indications, the analyst tells investors in a research note. The firm believes the company's IPH4502 could serve a "key niche" in Padcev-pretreated metastatic urothelial carcinoma, a $1.5B peak sales opportunity.
H.C. Wainwright
H.C. Wainwright
Buy -> Neutral
downgrade
2025-09-18
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
2025-09-18
downgrade
Buy -> Neutral
Reason
H.C. Wainwright downgraded Innate Pharma to Neutral from Buy without a price target. The company is prioritizing three assets, IP4502, lacutamab, and monalizumab, which do not have meaningful catalysts in the next 12 months, the analyst tells investors in a research note. The firm believes a "financing overhang is imminent" if Innate is unable to identify a partner for lacutamab development nor able monetize any of its assets.
Leerink
Outperform -> Market Perform
downgrade
$10 -> $2
2025-09-17
Reason
Leerink
Price Target
$10 -> $2
2025-09-17
downgrade
Outperform -> Market Perform
Reason
Leerink downgraded Innate Pharma to Market Perform from Outperform with a price target of $2, down from $10. The company relegating their proprietary antibody-based NK cell engager therapeutic platform to the background overly concentrates Innate's outlook to an antibody-drug conjugate strategy, which has an uncertain timing on generating clinical proof-of-concept outcomes, the analyst tells investors in a research note. Leerink adds that the lack of success in finding a partner to co-develop lacutamab and looming financing overhang reduces the firm's confidence in upside for the stock next year.
BTIG
Justin Zelin
Buy
initiated
$8
2025-07-28
Reason
BTIG
Justin Zelin
Price Target
$8
2025-07-28
initiated
Buy
Reason
BTIG analyst Justin Zelin initiated coverage of Innate Pharma with a Buy rating and $8 price target. Innate is a clinical-stage biotechnology company developing therapies for cancer and autoimmune disease, the analyst tells investors in a research note. The firm believes IPH4502 could address post Padcev treated bladder cancer patients and other Nectin-4 low tumor types. It sees the Initial Phase 1 data in late 2025 or early 2026 as a catalyst for the shares.
H.C. Wainwright
Buy
maintain
$11
2025-04-24
Reason
H.C. Wainwright
Price Target
$11
2025-04-24
maintain
Buy
Reason
H.C. Wainwright lowered the firm's price target on Innate Pharma to $11 from $11.50 and keeps a Buy rating on the shares. The firm postponed the U.S. launch of IPH6101 to 2029 from previously estimated 2027 and EU launch to 2030 from 2028.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Innate Pharma SA (IPHA.O) is -3.75, compared to its 5-year average forward P/E of -2.67. For a more detailed relative valuation and DCF analysis to assess Innate Pharma SA 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.67
Current PE
-3.75
Overvalued PE
10.00
Undervalued PE
-15.35

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-5.71
Current EV/EBITDA
-4.94
Overvalued EV/EBITDA
-2.75
Undervalued EV/EBITDA
-8.67

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
4.11
Current PS
3.86
Overvalued PS
5.60
Undervalued PS
2.62
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

IPHA News & Events

Events Timeline

(ET)
2025-11-10
05:55:13
Innate Pharma receives FDA approval to advance TELLOMAK 3 trial
select
2025-06-13 (ET)
2025-06-13
05:11:29
Innate Pharma presents preclinical data for IPH6501 at EHA
select
2025-05-23 (ET)
2025-05-23
05:11:18
Innate Pharma presents long-term follow-up data from TELLOMAK trial
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
11-28Businesswire
Innate Pharma Releases Share and Voting Rights Data as of November 27, 2025
  • Total Shares Disclosure: As of November 27, 2025, Innate Pharma reports 92,196,523 ordinary shares outstanding, indicating a stable capital structure that enhances investor confidence in the company's long-term growth prospects.
  • Voting Rights Information: The total theoretical voting rights stand at 92,962,943, with exercisable voting rights at 92,944,368, ensuring shareholder participation in governance and reflecting the company's commitment to transparency.
  • Compliance Adherence: This disclosure aligns with the French Commercial Code and AMF regulations, demonstrating Innate Pharma's rigorous approach to compliance, which helps build market trust.
  • Market Transparency Enhancement: By regularly releasing share and voting rights information, Innate Pharma not only boosts market transparency but also potentially attracts more investor interest in its innovative biotech products.
[object Object]
Preview
7.0
11-28Newsfilter
Innate Pharma Releases Share and Voting Rights Data as of November 27, 2025
  • Total Shares Disclosure: As of November 27, 2025, Innate Pharma has 92,196,523 ordinary shares outstanding, indicating a stable capital structure that enhances investor confidence in the company's long-term growth prospects.
  • Voting Rights Information: The total theoretical voting rights amount to 92,962,943, with exercisable voting rights at 92,944,368, ensuring shareholder participation in corporate decisions and reflecting the company's commitment to transparency.
  • Preferred Shares Status: The company holds 6,334 Preferred Shares from 2016 and 7,581 from 2017, indicating a diverse capital structure that may attract various types of investors.
  • Compliance Statement: This disclosure aligns with the requirements of the French stock market regulator, showcasing Innate Pharma's commitment to compliance and transparency, which helps to enhance market trust.
[object Object]
Preview
9.5
11-11Benzinga
Rocket Lab Shares Surge Over 9%; Check Out 20 Stocks Making Moves in Premarket Trading

  • Rocket Lab Financial Results: Rocket Lab Corp reported third-quarter revenue of $155.05 million, surpassing estimates, and a loss of three cents per share, which was better than the expected loss of 11 cents. The company's shares rose 9.3% in pre-market trading.

  • Fourth-Quarter Expectations: The company anticipates fourth-quarter revenue between $170 million and $180 million, slightly below estimates, and expects an adjusted EBITDA loss of $23 million to $29 million.

  • Pre-Market Stock Movements: Several stocks saw significant pre-market trading movements, with MSP Recovery Inc gaining 81% and Hitek Global Inc dropping 34.9% after previous fluctuations.

  • Other Notable Stocks: Companies like Kaltura Inc and RealReal Inc reported better-than-expected financial results, leading to notable gains in their stock prices, while others like Outset Medical Inc and Vor Biopharma Inc faced declines due to disappointing earnings or stock offerings.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Innate Pharma SA (IPHA) stock price today?

The current price of IPHA is 1.91 USD — it has increased 0.53 % in the last trading day.

arrow icon

What is Innate Pharma SA (IPHA)'s business?

Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.

arrow icon

What is the price predicton of IPHA Stock?

Wall Street analysts forecast IPHA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IPHA is 5.75 USD with a low forecast of 2.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Innate Pharma SA (IPHA)'s revenue for the last quarter?

Innate Pharma SA revenue for the last quarter amounts to NaN USD, decreased % YoY.

arrow icon

What is Innate Pharma SA (IPHA)'s earnings per share (EPS) for the last quarter?

Innate Pharma SA. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Innate Pharma SA (IPHA)'s fundamentals?

The market is revising Downward the revenue expectations for Innate Pharma S.A. (IPHA) for FY2025, with the revenue forecasts being adjusted by -80.26% over the past three months. During the same period, the stock price has changed by -6.82%.
arrow icon

How many employees does Innate Pharma SA (IPHA). have?

Innate Pharma SA (IPHA) has 181 emplpoyees as of December 05 2025.

arrow icon

What is Innate Pharma SA (IPHA) market cap?

Today IPHA has the market capitalization of 175.14M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free